ArticleBiology direct2026
Integrative transcriptomic profiling reveals NK cell exhaustion-associated prognostic genes and identifies CSF1 as a key immunoregulatory target in hepatocellular carcinoma.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) features a complex tumor immune microenvironment (TIME) where natural killer cell exhaustion (NKEX) facilitates immune evasion. Its regulatory networks and prognostic value remain insufficiently understood.
methodsWe integrated single-cell (GSE149614) and bulk RNA-seq (TCGA-LIHC) data. Following Seurat-based clustering, we utilized CellChat and pySCENIC for communication and transcription factor analysis. NKEX-associated modules were identified via gene set variation analysis and weighted gene co-expression network analysis. A prognostic signature was developed using LASSO-Cox regression and validated in an external cohort (ICGC). CSF1 was prioritized for validation through clinical immunohistochemistry, siRNA knockdown, and Western Blotting. Candidate compounds identified via reverse network pharmacology were validated through CCK-8 assays, docking, western blotting and quantitative PCR.
resultsSingle-cell analysis revealed pronounced NKEX and disrupted communication in HCC. A four-gene prognostic signature (AKR1B1, SMS, CSF1, CFL1) demonstrated robust predictive performance in both TCGA (1-year AUC: 0.759) and external validation cohorts. High-risk patients showed significantly poorer survival. CSF1 was markedly upregulated in HCC tissues; its silencing inhibited Huh7 cell migration and invasion while upregulating CXCL10 in Huh7 cells and CXCR3 in NK92 cells. Molecular docking and CCK-8 assays justified the dosage and identified punicalagin and evoden as potent inhibitors that significantly suppressed CSF1 expression at both mRNA and protein levels.
conclusionThrough integrated multi-omics and experimental validation, we characterized NKEX in HCC and established a robust prognostic signature. CSF1 emerged as a key immunomodulatory target. Punicalagin and evoden were identified as potential lead compounds to modulate the CSF1, offering a promising strategy to restore antitumor immunity in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.